Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia

Medical Oncology

Volumn 15, Issue 3, 1998, Pages 183-190

  Beksaç, Meral ^a   Arslan, Önder ^a   Koç, Haluk ^a   Akan, Hamdi ^a   Ilhan, Osman ^a   Arat, Mutlu ^a   Özean, Muhit ^a   Gürman, Günhan ^a   Konuk, Nahide ^a   Uysal, Akin ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Acute nonlymphoblastic leukemia; Daunorubicin; Idarubicin; Mitoxantron; Randomised trial

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 17944383575     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02821937     Document Type: Article

References (17)

1. Arlin Z et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphoblastic leukemia. Leukemia 1990; 4: 177-183.
2. Vogler WR et al. A phase III trial comparing idarubicin or daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group Experience. J Clin Oncol 1992; 10: 1103-1111.
3. Wiernik PH et al. Cytarabine plus Idarubicin or Daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992; 79: 313-319.
4. Berman E, Heller G, Santorsa J. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
5. Bishop JF et al. Etoposide in acute nonlymphoblastic leukemia. Blood 1990; 75: 27-32.
6. Burnett AK et al. The role of BMT in addition to intensive chemotherapy in AML in first CR: Results of the MRC AML-10 trial. Blood 1994; 84 (suppl 1): 252a.
7. Hann IM et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Resource Council's 10th Trial (MRC AML10). Blood 1997; 89: 2311-2318.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assn 1958; 53: 457-481.
9. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data Wiley: New York, 1980, pp 16-19.
10. Berman E. Chemotherapy in acute myelogenous leukemia: high dose, higher expectations. J Clin Oncol 1995; 13: 1-4.
11. Zittoun R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 322: 217-223.
12. Stone RM, Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin N Am 1993; 7: 47-64.
13. Berman E. New drugs in acute myelogenous leukemia: a review. J Clin Pharmacol 1992; 32: 296-309.
14. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-3273.
15. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997; 24: 57-69.
16. Wheatley K. (on behalf of the AML Collaborative Group MRC/CRF Cancer Studies Unit). Meta-analysis of randomized trials of idarabucin (idar) or mitoxantrone (mito) versus daunorubicin (dnr) as induction therapy for acute myeloid leukemia (AML). Blood 1995; 86 (suppl 1): 1724.
17. Bishop JF et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710-1717.